Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for ...

Speakers at the market include Sony's Shebnem Askin, One Piece exec producer Tetsu Fujimura and Elvis producer Schuyler Weiss.

Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $35.18, along with a high estimate of $52.00 and a low estimate of $18.00. This upward ...

() -Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.-based company's experimental drug, ...

Dr. Erin Theisen, who co-led the study, said this discovery could help treat many diseases where inflammation is a problem.

Tuberculosis (TB) remains a major global health challenge, affecting more than 10 million people annually worldwide, with ...

A study led by researchers at Queen Mary University of London has found that hormone replacement therapy (HRT) may help ...

Japan Aerospace Exploration Agency (JAXA) has selected ArcEdge Space to develop a satellite positioning system designed to complement existing GNSS.

A study led by researchers at Queen Mary University of London has found that hormone replacement therapy (HRT) may help ...